Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11571436 | BRISTOL | NA |
May, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Sep 1, 2023 |
Orphan Drug Exclusivity (ODE) | Sep 1, 2027 |
Market Authorisation Date: 01 September, 2020
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8846628 | CELGENE CORP | Oral formulations of cytidine analogs and methods of use thereof |
Jun, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Sep 1, 2023 |
Orphan Drug Exclusivity (ODE) | Sep 1, 2027 |
Market Authorisation Date: 01 September, 2020
Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not a...
Dosage: TABLET;ORAL
17
United States
5
European Union
4
Denmark
4
Slovenia
4
Lithuania
4
Hungary
4
Croatia
4
Portugal
4
Spain
4
Poland
3
Australia
3
Russia
3
Taiwan, Province of China
3
China
3
Japan
3
Canada
3
New Zealand
2
Israel
2
Mexico
2
Peru
2
Chile
2
Ukraine
1
South Africa
1
Turkey
1
Costa Rica
1
Singapore
1
Colombia
1
Brazil
1
Argentina
1
Cyprus
1
Malaysia
1
Korea, Republic of
1
Ecuador
1
Nicaragua
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic